Active	Status	Sponsor type	Region	Phase	Filter
12 Active 5 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gasbarrini, Antonio
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease	Recruiting	4	304	Europe, Canada, US, RoW	Vedolizumab	Alimentiv Inc., Takeda	Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn	01/27	09/28
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	3	160	Europe, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	08/24	09/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	207	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Ulcerative Colitis	09/26	08/27
PACER, NCT01801904 / 2010-024490-39: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer	Active, not recruiting	2	52	Europe	Panitumumab	National Cancer Institute, Naples, Azienda Ospedaliera G. Rummo	Metastatic Colorectal Cancer	12/24	12/24
NCT05016024: Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.	Completed	N/A	71	Europe	Colilen IBS, Placebo	Aboca Spa Societa' Agricola, IQVIA RDS, IQVIA Solutions	Irritable Bowel Syndrome	02/23	02/23
HDV Describe, NCT05723068: Burden of Hepatitis D Virus (HDV) Infection in Italy	Completed	N/A	515	Europe		University of Turin, Italy, Gilead Sciences	Chronic Hepatitis D	06/24	12/24
CROSSWORD, NCT05756582: Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students	Recruiting	N/A	2040	Europe	Prevalence of Latent Tuberculosis Infection	Eleonora Nucera	Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis Infection, Latent Tuberculosis, Health Care Associated Infection	06/26	12/26
Gigante, Giovanni
No trials found